CN116370513A - Notoginseng orally disintegrating tablet, and preparation method and application thereof - Google Patents
Notoginseng orally disintegrating tablet, and preparation method and application thereof Download PDFInfo
- Publication number
- CN116370513A CN116370513A CN202310371861.XA CN202310371861A CN116370513A CN 116370513 A CN116370513 A CN 116370513A CN 202310371861 A CN202310371861 A CN 202310371861A CN 116370513 A CN116370513 A CN 116370513A
- Authority
- CN
- China
- Prior art keywords
- parts
- notoginseng
- essence
- disintegrating tablet
- orally disintegrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 59
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 35
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 30
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 239000003765 sweetening agent Substances 0.000 claims abstract description 15
- 239000000945 filler Substances 0.000 claims abstract description 13
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 12
- 239000000080 wetting agent Substances 0.000 claims abstract description 12
- 239000000853 adhesive Substances 0.000 claims abstract description 9
- 230000001070 adhesive effect Effects 0.000 claims abstract description 8
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 16
- 229940069328 povidone Drugs 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 11
- 229940032147 starch Drugs 0.000 claims description 10
- 238000005550 wet granulation Methods 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 229920003081 Povidone K 30 Polymers 0.000 claims description 5
- 229920003082 Povidone K 90 Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 244000241235 Citrullus lanatus Species 0.000 claims description 4
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 241000167854 Bourreria succulenta Species 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 2
- 240000002319 Citrus sinensis Species 0.000 claims description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 244000290333 Vanilla fragrans Species 0.000 claims description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000019693 cherries Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229940107131 ginseng root Drugs 0.000 claims description 2
- -1 glidant Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 235000009569 green tea Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229910021487 silica fume Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 9
- 235000019658 bitter taste Nutrition 0.000 abstract description 6
- 238000011835 investigation Methods 0.000 abstract description 6
- 235000019640 taste Nutrition 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 208000019505 Deglutition disease Diseases 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 235000021092 sugar substitutes Nutrition 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 239000000686 essence Substances 0.000 description 17
- 238000005469 granulation Methods 0.000 description 17
- 230000003179 granulation Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000002994 raw material Substances 0.000 description 10
- 229940083542 sodium Drugs 0.000 description 6
- 235000015424 sodium Nutrition 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 3
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017472 Fumbling Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- NASRDENTZCCAPN-UHFFFAOYSA-N OC([Na])=O Chemical compound OC([Na])=O NASRDENTZCCAPN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pseudo-ginseng orally disintegrating tablet, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The notoginseng orally disintegrating tablet comprises 30-70 parts of notoginseng root powder, 20-60 parts of filler, 0-5 parts of adhesive, 5-20 parts of disintegrating agent, 0.5-3 parts of sweetener, 0.5-3 parts of aromatic, 0.5-2 parts of lubricant, 0.1-0.5 part of glidant and 15-30 parts of wetting agent. The invention prepares the notoginseng orally disintegrating tablet which contains notoginseng root powder and various auxiliary materials through experimental investigation, has the advantages of rapid disintegration time, good taste and the like, solves the defects of complicated taking process and the like of the traditional notoginseng powder, and is beneficial to dysphagia people to take; meanwhile, the filler is selected as a sugar substitute auxiliary material, so that the bitter taste of the pseudo-ginseng powder is covered, and meanwhile, the occurrence of blood sugar and decayed teeth of a user is not influenced, and the audience range of the pseudo-ginseng powder is greatly widened.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a pseudo-ginseng oral disintegrating tablet and a preparation method and application thereof.
Background
Notoginseng radix (Panax notoginseng (Burk.) F.H.Chen) is a plant of Panax of Araliaceae, also called Notoginseng radix, radix Stephaniae Sinicae, etc., and is mainly produced in Yunnan, guangxi, etc., and is a traditional rare Chinese medicinal material in China, and has been loaded in the past. Notoginseng radix is used as a medicine at root, has warm nature, sweet and slightly bitter taste, and has effects of removing blood stasis, stopping bleeding, detumescence and relieving pain. Can be used for treating hemoptysis, hematemesis, epistaxis, hematochezia, metrorrhagia, traumatic hemorrhage, thoracico-abdominal pain, and traumatic injury. Modern medical research shows that notoginseng also has the functions of improving myocardial blood supply, enhancing vascular elasticity and dilating arterial blood vessel. The notoginseng is taken frequently, so that cardiovascular and cerebrovascular diseases such as coronary heart disease, angina and the like can be prevented, and the notoginseng has great benefit for people with cardiovascular and cerebrovascular diseases.
Currently, the commercial pseudo-ginseng products mainly comprise pseudo-ginseng rhizome raw blocks and pseudo-ginseng rhizome powder, and are commonly used for food therapy or oral administration. The Notoginseng radix powder contains Notoginseng radix total saponin as effective component, and has bitter taste. The deposited total saponins of Notoginseng radix increase with growth age, and the bitter taste gradually deepens. In order to improve the acceptance of the users, sweet substances such as sucrose or honey and the like are added during eating, so that the eating mode is troublesome, and the utilization and acceptance of the pseudo-ginseng and the products thereof are restricted. Compared with Notoginseng radix rhizome blocks, liquid preparation, granule and capsule, notoginseng radix tablet has the advantages of simple storage, convenient carrying and use, and can improve the acceptance of Notoginseng radix product. In order to improve the utilization degree of pseudo-ginseng products, chinese patent CN 105641008A prepares pseudo-ginseng tablets by a supercritical extraction technology, and crospovidone, croscarmellose sodium and sodium carboxymethyl starch are added in the preparation process, so that the prepared tablets have longer disintegration time (more than 10 min). Chinese patent CN 1323667C developed a notoginseng dispersible tablet prepared by using notoginseng total saponins, but the dispersible tablet needs to be subjected to preliminary processing to extract notoginseng total saponins, and is not prepared by directly using notoginseng raw powder, so that some acceptation barriers exist for some audiences who are interested in taking the raw powder, and the preparation process is troublesome.
Some consumers may have problems with dysphagia and the like, while they receive less than adequate tablets for chewing. In order to improve the acceptance of users and the utilization rate of active ingredients in the pseudo-ginseng powder, the invention prepares the pseudo-ginseng orally disintegrating tablet which can be rapidly disintegrated in the oral cavity within 1min, has pleasant taste and expands the popularization and application of pseudo-ginseng products.
Disclosure of Invention
The invention aims to provide a pseudo-ginseng orally disintegrating tablet, a preparation method and application thereof, which are used for solving the problems in the prior art.
In order to achieve the above object, the present invention provides the following solutions:
the invention provides a pseudo-ginseng orally disintegrating tablet which comprises the following components in parts by weight:
30-70 parts of pseudo-ginseng root powder, 20-60 parts of filler, 0-5 parts of adhesive, 5-20 parts of disintegrating agent, 0.5-3 parts of sweetener, 0.5-3 parts of aromatic, 0.5-2 parts of lubricant, 0.1-0.5 part of glidant and 15-30 parts of wetting agent.
Further, the filler includes one or more of xylitol, mannitol, sorbitol, erythritol, cyclodextrin, starch, lactose, pregelatinized starch, microcrystalline cellulose, calcium carbonate, and calcium phosphate.
Further, the binder comprises one or more of starch, pregelatinized starch, sucrose, glucose, methylcellulose, hydroxypropyl cellulose, hypromellose, sodium carboxymethyl cellulose, ethylcellulose, povidone, gelatin, polyethylene glycol, and sodium alginate.
Further, the disintegrating agent comprises one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, crospovidone, microcrystalline cellulose, alginic acid and sodium alginate.
Further, the sweetener comprises one or more of glucose, sucrose, stevioside, saccharin sodium, aspartame and sucralose;
the aromatic comprises one or more of strawberry essence, grape essence, peach essence, lemon essence, watermelon essence, cherry essence, hawthorn essence, sweet orange essence, peppermint essence, green tea essence, vanilla essence and sweet essence;
the lubricant comprises one or more of stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol and lauryl sulfate;
the glidant comprises one or more of micropowder silica gel and talcum powder;
the wetting agent comprises water or ethanol with the volume fraction of 10-60%.
Further, the paint comprises the following components in parts by weight:
50 parts of notoginseng root powder, 29.4 parts of xylitol, 3 parts of povidone, 15 parts of crospovidone, 1 part of sucralose, 1 part of watermelon essence, 0.5 part of magnesium stearate, 0.1 part of micro silica gel and 20 parts of ethanol with the volume fraction of 50 percent.
Further, the povidone includes povidone K30 or povidone K90.
The invention also provides a preparation method of the pseudo-ginseng oral disintegrating tablet, which comprises the following steps:
weighing according to parts by weight, mixing uniformly radix notoginseng powder, filler, adhesive and 1/2-2/3 of disintegrating agent, adding wetting agent to prepare wet granules, sieving, drying, granulating, adding sweetener, glidant, lubricant and 1/3-1/2 of disintegrating agent, mixing uniformly, tabletting to obtain the radix notoginseng orally disintegrating tablet.
Further, the wet granules are produced by a high-speed shearing granulator through a wet granulation method.
The invention also provides an application of the pseudo-ginseng oral disintegrating tablet in preparing health-care food for preventing cardiovascular and cerebrovascular diseases.
The invention discloses the following technical effects:
1. the filler used in the invention is mainly sugar-substituted auxiliary materials, has the function of covering up the bitter taste of the pseudo-ginseng powder, is not absorbed by human body, does not change the blood sugar change and the occurrence of decayed teeth in the body of a user, and is beneficial to improving the acceptance of the user.
2. Compared with dry granulation, wet granulation is the most widely used granulation mode at present, the process and equipment are more mature, and meanwhile, the granules obtained by the wet granulation have the advantages of attractive appearance, good fluidity, good wear resistance, good compression formability and the like; according to the invention, the disintegrating agent is added by internal and external addition in the preparation process, so that the disintegrating time effect can be obviously shortened, and the disintegrating effect is better.
3. Different auxiliary materials can be added in the preparation process of the pseudo-ginseng tablet prepared by the invention to improve the flavor of the tablet, so that the flavor of the tablet is more diversified, and the tablet is suitable for the demands of different people.
4. The notoginseng powder orally disintegrating tablet prepared by the invention can be rapidly disintegrated in the oral cavity within 1min through saliva, is very friendly to dysphagia people, and can improve the utilization rate of active ingredients in the notoginseng powder through rapid disintegration in the oral cavity.
The invention prepares the notoginseng orally disintegrating tablet through a large number of experiments, which contains notoginseng root powder with a certain proportion and auxiliary materials with a certain proportion. The orally disintegrating tablet has the advantages of rapid disintegration time, good taste, and the like, overcomes the defects of complicated administration process and the like of the traditional pseudo-ginseng powder, and is beneficial to dysphagia people. Meanwhile, the filler is selected as a sugar substitute auxiliary material, so that the bitter taste of the pseudo-ginseng powder is covered, and meanwhile, the occurrence of blood sugar and decayed teeth of a user is not influenced, and the audience range of the pseudo-ginseng powder is greatly widened.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples of the present invention are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
The notoginseng root powder and the auxiliary materials used in the invention have finer particle size, and the selected raw materials and auxiliary materials are required to be granulated in order to improve the fluidity and the disintegration effect. Wet granulation is one of the most traditional granulation techniques, and the granules prepared by the wet granulation have good fluidity and density, meanwhile, the use of liquid is involved in the granulation process, the dust generation is less in the production process, and the pollution to air is also less. Therefore, wet granulation is selected as the granulation mode in the production process.
As a simple and effective taste masking mode, the sucrose auxiliary material is used as a filling agent, so that the taste masking effect can be well achieved. The invention discovers that the crowd who purchases the pseudo-ginseng powder for taking in the market at present is generally middle-aged and elderly people, and hopefully can improve the health problem of the crowd by taking the pseudo-ginseng powder for a long time. However, at the same time, the part of people may have the problem of 'three highs'. The use of sucrose-based excipients can greatly limit the use of such people. Through continuous fumbling, the invention selects the sugar substitute auxiliary material as the filling agent, and can not cause the problems of blood sugar, decayed tooth and the like of a user while masking the taste with high efficiency.
Example 1
The raw materials of the notoginseng oral disintegrating tablet are shown in table 1:
TABLE 1
The preparation method of the pseudo-ginseng oral disintegrating tablet comprises the following steps: weighing Notoginseng radix powder, filler, disintegrating agent and binder in proportion, mixing, adding wetting agent to obtain wet granule, wet granulating with high speed shearing granulator to obtain wet granule, sieving wet granule, drying, granulating, adding sweetener and glidant, mixing, adding lubricant, and tabletting.
In the preparation process of the notoginseng powder orally disintegrating tablet, the viscosity of the notoginseng total saponins as an active ingredient in the notoginseng powder is extremely high, so that the granulation process is smoothly realized, and the influence of different wetting agents and contents on the granulation process is examined based on the formula of the table 1. See in particular table 2.
TABLE 2 types and contents of wetting agents
It has been found that in order to achieve good granulation, ethanol or water with a low volume concentration (10-60%) is preferably used as wetting agent in the wet granulation process, and the amount of wetting agent is more than 10 parts, preferably 20 parts, for the following investigation.
Example 2
The invention discovers that the cellulose content in the pseudo-ginseng rootstock powder is higher, and the adhesive has a larger influence on the particle size distribution of particles in the granulating process. The proper adhesive type and the proper addition content can greatly improve the granulating effect, increase the fluidity of the granules and facilitate the subsequent further processing. In order to better realize the granulating effect, the particle size distribution of the granules is more uniform, and the adhesive is added in the preparation process. Based on the raw material formulation of example 1, the invention explores the influence of several binders and amounts on the pelletization process, and is shown in Table 3.
TABLE 3 kinds and amounts of binders
| Adhesive agent | Dosage (weight portions) | Granulating effect | |
| Scheme one | Povidone K30 | 2.5 | Granulation of |
| Scheme II | Povidone K30 | 5 | Granulation of |
| Scheme III | Povidone K30 | 6 | Paste form |
| Scheme IV | Povidone K90 | 2.5 | Granulation of |
| Scheme five | Povidone K90 | 5 | Paste form |
| Scheme six | Povidone K90 | 6 | Paste form |
| Scheme seven | Polyethylene glycol 6000 | 2.5 | Granulation of |
| Scheme eight | Polyethylene glycol 6000 | 5.0 | Granulation of |
| Scheme nine | Polyethylene glycol 6000 | 6.0 | Paste form |
| Scheme ten | Polyethylene glycol 8000 | 2.5 | Granulation of |
| Scheme eleven | Polyethylene glycol 8000 | 5.0 | Granulation of |
| Scheme twelve | Polyethylene glycol 8000 | 6.0 | Paste form |
It has been found by investigation that in order to achieve a better granulation effect, in the wet granulation process, a polymer with a lower molecular weight is preferably used as the binder, and the amount of the polymer is not more than 5 parts, otherwise, the polymer is very easy to form a soft paste in the granulation process, and the granulation cannot be successfully performed.
Example 3
The prepared tablet is pseudo-ginseng powder orally disintegrating tablet, and in order to achieve the aim of rapid disintegration, a disintegrating agent is added in the preparation process, and the type and the adding mode of the disintegrating agent have great influence on the disintegration of the tablet. Based on the raw material formulation of example 1, the present invention examined the influence of several kinds of disintegrants and the addition modes of the disintegrants on the disintegration of tablets, and specifically, see table 4.
TABLE 4 types of disintegrants and modes of addition
| Disintegrating agent | Addition mode | Disintegrating effect(s) | |
| Scheme one | Microcrystalline cellulose | Internal addition | 80 |
| Scheme II | Microcrystalline cellulose | External addition | 80 |
| Scheme III | Microcrystalline cellulose | Internal and external addition | 70 |
| Scheme IV | Sodium carboxymethyl starch | Internal addition | 55 |
| Scheme five | Sodium carboxymethyl starch | External addition | 50 |
| Scheme six | Sodium carboxymethyl starch | Internal and external addition | 45 |
| Scheme seven | Crosslinked povidone | Internal addition | 40 |
| Scheme eight | Crosslinked povidone | External addition | 60 |
| Scheme nine | Crosslinked povidone | Internal and external addition | 30 |
The internal addition preparation process is the same as in example 1; the external addition is to dry all disintegrating agents, granulate and add; the internal and external addition is to add 1/2 of the disintegrating agent in the same preparation process as in the example 1, and add the rest disintegrating agent after drying and granulating.
According to the research, in order to achieve a better disintegrating effect, in the wet granulation process, crospovidone or sodium carboxymethyl starch or both can be selected as a disintegrating agent, and the adding mode is combined with the internal addition and the external addition, so that the good disintegrating effect can be achieved.
In order to better realize the disintegration effect, the invention carries out partial formula screening based on the above preferred formula, and the specific formula is shown in table 5.
Table 5 prescription composition and amount (parts by weight)
Table 6 five different investigation indices and results
The results of the above examination show (Table 6) that the indices of the second formulation are all optimal, indicating that the disintegration effect is best when crospovidone is used alone.
Example 4
The raw materials of the notoginseng oral disintegrating tablet are shown in table 7:
TABLE 7
The preparation process comprises the following steps:
pulverizing adjuvants, sieving with 80 mesh sieve, weighing Notoginseng radix powder, xylitol, povidone and 2/3 of cross-linked povidone according to the above formula, mixing, adding 20% ethanol, making into soft mass, sieving to obtain wet granule, drying, grading, adding 1/3 of cross-linked povidone, sweetener, essence, micropowder silica gel and magnesium stearate, mixing, and tabletting (pressure 5 KN).
Example 5
The raw materials of the notoginseng oral disintegrating tablet are shown in table 8:
TABLE 8
The preparation process comprises the following steps:
pulverizing adjuvants, sieving with 80 mesh sieve, weighing Notoginseng radix powder, xylitol, mannitol, polyethylene glycol (Mw=6000) and 1/2 crosslinked povidone according to the above formula, mixing, adding appropriate amount of 10% ethanol, making into soft mass, sieving, granulating, drying, grading, adding 1/2 crosslinked povidone, sweetener, essence, micropowder silica gel and magnesium stearate, mixing, and tabletting (pressure is 10 KN).
Example 6
The raw materials of the notoginseng oral disintegrating tablet are shown in table 9:
TABLE 9
The preparation process comprises the following steps: the procedure was as in example 5.
Example 7
The raw materials of the notoginseng oral disintegrating tablet are shown in table 10:
table 10
The preparation process comprises the following steps:
pulverizing adjuvants, sieving with 80 mesh sieve, weighing Notoginseng radix powder, mannitol, polyethylene glycol (Mw=6000) and 2/3 carboxyl sodium starch according to the above formula, mixing, adding appropriate amount of 20% ethanol, making into soft material, sieving to obtain wet granule, drying, grading, adding 1/3 carboxymethyl sodium starch, sweetener, essence, micropowder silica gel and magnesium stearate, mixing, and tabletting (pressure of 8 KN).
Example 8
The raw materials of the notoginseng oral disintegrating tablet are shown in table 11:
TABLE 11
The preparation process comprises the following steps: the procedure is as in example 7.
Example 9
The raw materials of the notoginseng oral disintegrating tablet are shown in table 12:
table 12
The preparation process comprises the following steps:
pulverizing adjuvants, sieving with 80 mesh sieve, weighing Notoginseng radix powder, xylitol, polyethylene glycol (Mw=8000) and 1/2 crosslinked povidone according to the above formula, mixing, adding appropriate amount of 10% ethanol, making into soft material, sieving to obtain wet granule, drying, grading, adding 1/2 crosslinked povidone, sweetener, essence, micropowder silica gel and magnesium stearate, mixing, and tabletting (pressure 10 KN).
Each index of the notoginseng oral disintegrating tablets prepared in examples 4 to 9 was examined, and the results were as follows:
table 13 investigation index and results of the samples prepared in examples 4 to 9
| Investigation index | Example 4 | Example 5 | Example 6 | Example 7 | Example 8 | Example 9 |
| Appearance of | Smooth and beautiful | Smooth and beautiful | Smooth and beautiful | Smooth and beautiful | Smooth and beautiful | Smooth and beautiful |
| Compressibility of | Good (good) | Good (good) | Good (good) | Good (good) | Good (good) | Good (good) |
| Weight difference | Meets the regulations | Meets the regulations | Meets the regulations | Meets the regulations | Meets the regulations | Meets the regulations |
| Time limit of disintegration | 40s | 45s | 50s | 55s | 40s | 55s |
The results show that the orally disintegrating tablets prepared in examples 4-9 all meet the regulations on appearance, compressibility and weight difference, and the disintegration time is within 1 min.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (10)
1. The notoginseng orally disintegrating tablet is characterized by comprising the following components in parts by weight:
30-70 parts of pseudo-ginseng root powder, 20-60 parts of filler, 0-5 parts of adhesive, 5-20 parts of disintegrating agent, 0.5-3 parts of sweetener, 0.5-3 parts of aromatic, 0.5-2 parts of lubricant, 0.1-0.5 part of glidant and 15-30 parts of wetting agent.
2. The notoginseng orally disintegrating tablet of claim 1, wherein the filler comprises one or more of xylitol, mannitol, sorbitol, erythritol, cyclodextrin, starch, lactose, pregelatinized starch, microcrystalline cellulose, calcium carbonate, and calcium phosphate.
3. The notoginseng orally disintegrating tablet of claim 1, wherein the binder comprises one or more of starch, pregelatinized starch, sucrose, glucose, methylcellulose, hydroxypropyl cellulose, hypromellose, sodium carboxymethyl cellulose, ethylcellulose, povidone, gelatin, polyethylene glycol, and sodium alginate.
4. The notoginseng orally disintegrating tablet of claim 1, wherein the disintegrant comprises one or more of dry starch, sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, croscarmellose sodium, crospovidone, microcrystalline cellulose, alginic acid, and sodium alginate.
5. The notoginseng orally disintegrating tablet of claim 1, wherein the sweetener comprises one or more of glucose, sucrose, stevioside, sodium saccharin, aspartame, sucralose;
the aromatic comprises one or more of strawberry essence, grape essence, peach essence, lemon essence, watermelon essence, cherry essence, hawthorn essence, sweet orange essence, peppermint essence, green tea essence, vanilla essence and sweet essence;
the lubricant comprises one or more of stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol and lauryl sulfate;
the glidant comprises one or more of micropowder silica gel and talcum powder;
the wetting agent comprises water or ethanol with the volume fraction of 10-60%.
6. The notoginseng orally disintegrating tablet according to claim 1, comprising the following components in parts by weight:
50 parts of notoginseng root powder, 29.4 parts of xylitol, 3 parts of povidone, 15 parts of crospovidone, 1 part of sucralose, 1 part of watermelon essence, 0.5 part of magnesium stearate, 0.1 part of micro silica gel and 20 parts of ethanol with the volume fraction of 50 percent.
7. The notoginseng orally disintegrating tablet of claim 6, wherein the povidone comprises povidone K30 or povidone K90.
8. A method for preparing the notoginseng oral disintegrating tablet according to claim 1, comprising the following steps:
weighing according to parts by weight, mixing uniformly radix notoginseng powder, filler, adhesive and 1/2-2/3 of disintegrating agent, adding wetting agent to prepare wet granules, sieving, drying, granulating, adding sweetener, glidant, lubricant and 1/3-1/2 of disintegrating agent, mixing uniformly, tabletting to obtain the radix notoginseng orally disintegrating tablet.
9. The method of claim 8, wherein the wet granulation is performed by a high-speed shear granulator.
10. Use of an orally disintegrating tablet of pseudo-ginseng according to any one of claims 1-6 in the preparation of a health food for preventing cardiovascular and cerebrovascular diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310371861.XA CN116370513A (en) | 2023-04-10 | 2023-04-10 | Notoginseng orally disintegrating tablet, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310371861.XA CN116370513A (en) | 2023-04-10 | 2023-04-10 | Notoginseng orally disintegrating tablet, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116370513A true CN116370513A (en) | 2023-07-04 |
Family
ID=86972907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310371861.XA Pending CN116370513A (en) | 2023-04-10 | 2023-04-10 | Notoginseng orally disintegrating tablet, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116370513A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739533A (en) * | 2004-08-27 | 2006-03-01 | 郑州三创释药技术有限公司 | Oral disintegrating notoginseng total saponin tablet and its prepn process |
| CN1742743A (en) * | 2005-09-21 | 2006-03-08 | 重庆康刻尔制药有限公司 | Pseudo-ginseng saponin oral disintegration tablet and preparing method |
-
2023
- 2023-04-10 CN CN202310371861.XA patent/CN116370513A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739533A (en) * | 2004-08-27 | 2006-03-01 | 郑州三创释药技术有限公司 | Oral disintegrating notoginseng total saponin tablet and its prepn process |
| CN1742743A (en) * | 2005-09-21 | 2006-03-08 | 重庆康刻尔制药有限公司 | Pseudo-ginseng saponin oral disintegration tablet and preparing method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772444A (en) | Method for processing traditional Chinese medicinal ultramicro wall-broken oral tablet slices | |
| CN102772440A (en) | Processing method of ultra-micro wall-breaking oral-tablet decoction pieces by traditional Chinese medicines | |
| CN113384647B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating acute lung injury | |
| CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
| CN100374119C (en) | Pseudo-ginseng saponin oral disintegration tablet and preparing method | |
| CN107789328A (en) | A kind of oral disintegrating tablet containing Doneppezil Hydrochloride and preparation method thereof | |
| CN102793839A (en) | Taste-modifying Chinese medicinal preparation and preparation method thereof | |
| CN116370513A (en) | Notoginseng orally disintegrating tablet, and preparation method and application thereof | |
| CN100518720C (en) | Orally quick-acting tablet of ginseng stem leaf saponin including orally disintegrating tablet and dispersible tablet and method for preparing the same | |
| CN110624020A (en) | Compound calyx seu fructus physalis tablet and preparation method thereof | |
| CN100336502C (en) | Yunnan Manyleaf paris Rhizome extract ora disintegration tablet and its preparing process | |
| CN100400034C (en) | Dispersible tablet of Vitamin C and Lonicera and Forsythia and preparing method thereof | |
| CN102772439A (en) | Processing method of ultra-micro wall-breaking capsule-preparation decoction pieces by traditional Chinese medicines | |
| CN107137366A (en) | A kind of Orally disintegrating tablet of ambroxol hydrochloride and preparation method thereof | |
| CN106580898A (en) | Breviscapine dispersible tablet and preparing method thereof | |
| CN100509048C (en) | Jinwu Gutong tablet and preparing method thereof | |
| CN100506219C (en) | Notoginseng hemostatic and its preparing method | |
| CN112587487B (en) | Echinacoside orally disintegrating tablet and preparation method thereof | |
| CN102772441A (en) | Method for processing traditional Chinese medicinal ultramicro wall-broken capsule slices | |
| CN102949485A (en) | Traditional Chinese medical dispersible tablet for acute appendicitis and preparation method thereof | |
| CN116350736B (en) | Traditional Chinese medicine composition for preventing and treating breast nodules | |
| CN113456756B (en) | Jujube kernel-dendrobium traditional Chinese medicine composition for improving insomnia of middle-aged and elderly women and preparation method thereof | |
| CN114306472B (en) | Kidney-tonifying and qi-benefiting composition containing acanthopanax senticosus and preparation and application thereof | |
| CN107049961A (en) | A kind of Study on Supermicro-pulverization of Traditional Chinese Drugs mouthful collapses particulate composition and preparation method thereof | |
| CN1927372A (en) | Antiviral dispersant tablet and method for making same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |